---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-24-000022"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:09:30.836211+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance

## Summary
- Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).
- Core pharma revenue up 5% actual/6% CC; LEQEMBI global in-market sales ~$40M (US ~$30M).
- SKYCLARYS rev $100M, ZURZUVAE rev $15M; completed HI-Bio acquisition expanding immunology pipeline.
- Raised FY2024 Non-GAAP EPS guidance to $15.75-$16.25 (mid-point ~9% growth vs FY2023).
- Retains Biosimilars business; expects operating income growth mid- to high-teen % and margin improvement.

## SEC filing metadata
- accession: 0000875045-24-000022
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/0000875045-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504524000022/biib-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-24-000022
- JSON: https://secwatch.observer/filing/0000875045-24-000022.json
- Plain text: https://secwatch.observer/filing/0000875045-24-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.